McKesson Corporation vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.26 (market cap $21.89B). The key difference: McKesson Corporation is far larger — about 5× Consumer Discretionary Select Sector SPDR Fund's market cap, and McKesson Corporation pays a 0.4% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| MCK | XLY | |
|---|---|---|
Market Cap | $108.46B | $21.89B |
Volume | 712,607 | 5,690,342 |
Sector | Health | — |
52-Week High | $995.69 | $124.52 |
52-Week Low | $725.17 | $105.64 |
Typical Hold Time | 74 Days | 114 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
XLY trades at $111.36, down 0.35% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF has underperformed the broader market in 2026, declining over 7% year-to-date while consumer staples have gained. Analyst consensus remains strongly bullish with 100% buy ratings, though recent news highlights persistent underperformance concerns and inflationary pressures on consumer discretionary spending.
The outlook for XLY hinges on consumer resilience amid inflation, with potential catalysts from holiday spending growth and 'funflation' trends. Key risks include continued underperformance versus the S&P 500, inflation pressure on household budgets, and concentration in top holdings. Technical support sits at $110 with resistance at $112-113, requiring a breakout for sustained momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →